NCT04565171View on ClinicalTrials.gov

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

May 7, 2022

Study Completion Date

May 7, 2022

Conditions
Renal Impairment
Interventions
DRUG

Yimitasvir Phosphate Capsule

DAG181 100 mg (100 mg Capsule) administered orally

Trial Locations (1)

610000

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY